“The present situation has exposed some structural weaknesses during the EU’s medicines offer chain as well as a high dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides claimed. She proposed that offer chain troubles be addressed within an EU pharmaceutical system envisioned for being introduced b